PUT - SPRINTER OPEN END - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 09:12:59 29/05/2024 BST | ||
| 19.34 EUR | -2.62% |
|
| Current month | -11.65% | ||
| 1 month | -24.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 19.34 | -2.62% |
| 28/05/24 | 19.86 | +5.36% |
| 27/05/24 | 18.85 | -1.98% |
| 24/05/24 | 19.23 | +0.47% |
| 23/05/24 | 19.14 | -4.63% |
Real-time Boerse Frankfurt Warrants
Last update May 29, 2024 at 09:12 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD1JH4 |
| ISIN | DE000VD1JH48 |
| Date issued | 05/03/2024 |
| Strike | 1,016 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.74 € |
|---|---|
| Lowest since issue | 18.79 € |
| Spread | 0.3 € |
| Spread % | 1.48% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
- Stock Market
- Certificates
- Certificat
